Fund Holdings — Merck & Co., Inc.

Total Portfolio Value
$164.28M
Total Bought
$1.79M
Total Sold
$2.62M
Net Transaction
-$827.5K
Filing Period:
Securities
▲▼
SharesValue ($K)
Q4 2024
▲▼
Q1 2025
▲▼
Change
▲▼
Q4 2024
▲▼
Q1 2025
▲▼
Weight (%)
▲▼
Change
▲▼
EVAXION BIOTECH A/S542,2791,214,126+671,8474582,2461.37%+1,788
LAVA THERAPEUTICS NV1,149,3451,149,34501,0931,4600.89%+367
NEUPHORIA THERAPEUTICS INC10,02710,027034580.04%+23
CARISMA THERAPEUTICS INC1,473,2401,473,24006174570.28%-160
XILIO THERAPEUTICS INC(XLO)1,483,7581,483,75801,4171,0750.65%-342
VIRIDIAN THERAPEUTICS INC(VRDN)93,41493,41401,7911,2590.77%-532
ALECTOR INC3,545,7193,545,71906,7014,3612.65%-2,340
ABSCI CORPORATION998,1630-998,1632,6150—-2,615
SUTRO BIOPHARMA INC(STRO)2,723,5092,723,50905,0111,7721.08%-3,239
KYMERA THERAPEUTICS INC(KYMR)772,165772,165031,06421,13412.86%-9,930
ENTRADA THERAPEUTICS INC(TRDA)1,739,7681,739,768030,08115,7289.57%-14,353
MODERNA INC(MRNA)2,308,1902,308,190095,97565,43739.83%-30,537
PERSONALIS INC(PSNL)14,044,94314,044,943081,18049,29830.01%-31,882
Page 1 of 1
Merck & Co., Inc. — 13F Holdings — Q1 2025 | TickerTrail